SCHEMBL5012740

SCHEMBL5012740

CCCCCCC(CO)(CO)CNC

nearest known ligand 0.39

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
EPHX1 P07099 1/20 0.39
LMNA P02545 3/20 0.37
ALDH1A1 P00352 1/20 0.37
HSD17B10 Q99714 1/20 0.37
MEN1 O00255 1/20 0.37
KMT2A Q03164 1/20 0.37
TSHR P16473 1/20 0.37
GGPS1 O95749 3/20 0.36
TNNC1 P63316 5/20 0.36
SGPL1 O95470 1/20 0.36
S1PR4 O95977 1/20 0.36
S1PR1 P21453 1/20 0.36
GPR183 P32249 1/20 0.36
CERS2 Q96G23 1/20 0.36
S1PR3 Q99500 1/20 0.36
S1PR5 Q9H228 1/20 0.36
LPAR3 Q9UBY5 3/20 0.35
LPAR2 Q9HBW0 1/20 0.35
FDPS P14324 5/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5065718 1.00 EPHX1 (0.39) EPHX1LMNAALDH1A1HSD17B10MEN1
SCHEMBL5013498 0.91 EPHX1 (0.32) EPHX1ALDH1A1TNNC1SGPL1S1PR4
SCHEMBL3730641 0.82 LMNA (0.48) LMNAALDH1A1HSD17B10MEN1KMT2A
SCHEMBL7044918 0.82 LMNA (0.48) LMNAALDH1A1HSD17B10MEN1KMT2A
SCHEMBL2109769 0.82 LMNA (0.48) LMNAALDH1A1HSD17B10MEN1KMT2A
SCHEMBL8205797 0.82 LMNA (0.48) LMNAALDH1A1HSD17B10MEN1KMT2A
SCHEMBL7796853 0.82 LMNA (0.48) LMNAALDH1A1HSD17B10MEN1KMT2A
SCHEMBL9354133 0.82 LMNA (0.48) LMNAALDH1A1HSD17B10MEN1KMT2A
SCHEMBL20873213 0.82 LMNA (0.48) LMNAALDH1A1HSD17B10MEN1KMT2A
SCHEMBL7796670 0.82 LMNA (0.48) LMNAALDH1A1HSD17B10MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1917268-A2 PREPARATION OF 2,6-DIOXA-7-AZA-BICYCLO(2.2.2)OCTANES, AND THEIR USE IN COATINGS E.I.Du pont de nemours and company (US) 2008-05-07 EP disclosed
WO-2007024835-A2 PREPARATION OF 2,6-DIOXA-7-AZA-BICYCLO[2.2.2]OCTANES, AND THEIR USE IN COATINGS E. I. DU PONT DE NEMOURS AND COMPANY (US) 2007-03-01 WO disclosed
US-20070049752-A1 Preparation of 2,6-dioxa-7-aza-bicyclo[2.2.2] octanes E. I. DU PONT DE NEMOURS AND COMPANY 2007-03-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070049752-A1 Preparation of 2,6-dioxa-7-aza-bicyclo[2.2.2] octanes OR10J3, DNMT1, TET3 EPHX1 1065/4885LMNA 2363/4885ALDH1A1 672/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.